Genomic cancer testing refers to a set of procedures and techniques used to detect mutations in genes or expression levels of cancer-related genes for cancer diagnosis, prognosis, and treatment decisions. It employs advanced molecular technologies including Next Generation Sequencing (NGS), Sanger sequencing, microarrays, and PCR for detecting DNA variations in tumor and cancer cells. Genomic testing provides an accurate assessment of cancer risks, ensures targeted therapy, predicts treatment efficacy, facilitates precision medicine, and improves clinical outcomes.

The global genomic cancer testing market is estimated to be valued at US$ 8.6 Bn in 2023 and is expected to exhibit a CAGR of 7.8% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Dynamics:
Increasing prevalence of cancer owing to sedentary lifestyles, obesity, smoking, alcohol consumption, and environmental factors is a key driver augmenting growth of the genomic cancer testing market. According to statistics by the World Health Organization, cancer accounted for around 10 million deaths globally in 2020. Another driver favoring the market is growing application of genomic testing for selecting appropriate treatment plans and monitoring disease progression. For instance, genomic testing is used to analyze cancer cells and predict response to targeted therapies and immunotherapy. Further, ongoing research efforts to understand complex genomic changes in cancer and development of more advanced diagnostic tools will continue boosting market revenues. However, high costs associated with genomic testing and lack of clear reimbursement for such tests in developing nations hampers market growth to some extent.

SWOT Analysis
Strength: Genomic cancer testing provides a comprehensive genetic profile of tumors and helps characterize their underlying genomic drivers. This allows oncologists to select customized treatment plans for patients. In addition, genomic cancer testing aids in early cancer detection by identifying genetic mutations long before clinical signs appear. It also helps monitor cancer recurrence by detecting residual disease or new primary cancers.

Weakness: Genomic cancer testing is still an emerging technology and is not universally covered by medical insurance. The cost of whole genome sequencing is also quite high, making genomic cancer testing unaffordable for many. Furthermore, interpreting the clinical significance of many gene mutations remains a challenge.

Opportunity: The reduction in genome sequencing costs in recent years is expected to make genomic cancer testing more accessible. Growing awareness about the clinical benefits of personalized cancer care is also driving increased adoption. Furthermore, emerging therapies that target specific gene mutations provide opportunities for genomic profiling to maximize treatment effectiveness.

Threats: Regulatory uncertainty around the clinical validity and utility of genomic cancer testing poses challenges. Reimbursement policies vary greatly between countries and medical insurance providers, restricting the ability of healthcare facilities and patients to access these tests. Ethical and legal issues involving genetic privacy further complicate the integration of genomic information into clinical practice.

Key Takeaways

Global Genomic Cancer Testing Market Size is expected to witness high growth over the forecast period of 2023 to 2030.

North America currently dominates the market due to the rising incidence of cancer, growing demand for personalized medicine, favorable reimbursement policies, and presence of leading market players. Furthermore, growing awareness among oncologists and patients coupled with reducing costs of whole genome sequencing are fueling market expansion in the region.
Europe is the second largest and one of the fastest growing markets for genomic cancer testing. Major factors driving market growth include the increasing cancer burden, rising healthcare expenditure, growing geriatric population, and availability of advanced genomic technologies. Furthermore, the Europe Union has provided funding and initiated programs that promote research, development and clinical adoption of precision oncology across the region.

Some of the key players operating in the genomic cancer testing market are F. Hoffmann-La Roche Ltd, Myriad Genetics, Inc., Illumina, Inc., Thermo Fisher Scientific Inc., Agilent Technologies, Inc., QIAGEN, Bio-Rad Laboratories, Inc., GE Healthcare Dharmacon Inc., and Koninklijke Philips N.V. These companies have gained a strong foothold through partnerships, new product launches, and acquisitions. Further consolidation in the industry is expected with large players seeking opportunities for portfolio expansion in high-growth markets and technologies.

Get More Insights on this topic- https://www.dailyprbulletin.com/genomic-cancer-testing-market-value-and-growth-analysis/